AGE RELATED MACULAR DEGENERATION (ARMD)
Clinical trials for AGE RELATED MACULAR DEGENERATION (ARMD) explained in plain language.
Never miss a new study
Get alerted when new AGE RELATED MACULAR DEGENERATION (ARMD) trials appear
Sign up with your email to follow new studies for AGE RELATED MACULAR DEGENERATION (ARMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot could slow blindness in millions
Disease control OngoingThis study tests a daily shot called elamipretide to see if it can slow the loss of light-sensing cells in the eyes of people with dry age-related macular degeneration (AMD). About 313 adults aged 55 and older with early vision damage will receive either the drug or a placebo for…
Matched conditions: AGE RELATED MACULAR DEGENERATION (ARMD)
Phase: PHASE3 • Sponsor: Stealth BioTherapeutics Inc. • Aim: Disease control
Last updated May 05, 2026 11:54 UTC
-
Can your dinner save your eyesight? new study investigates
Knowledge-focused OngoingThis study looks at how genetics, diet (especially Mediterranean diet), lifestyle habits, and chronic medication together influence the risk of developing age-related macular degeneration (AMD). Researchers will examine 1800 adults from the Lousã region, collecting medical histor…
Matched conditions: AGE RELATED MACULAR DEGENERATION (ARMD)
Phase: NA • Sponsor: Association for Innovation and Biomedical Research on Light and Image • Aim: Knowledge-focused
Last updated May 04, 2026 16:24 UTC